Directive 2000/54/EC of the European Parliament and of the Council of 18 September 2000 on the protection of workers from risks related to exposure to biological agents at work (seventh individual directive within the meaning of Article 16(1) of Directive 89/391/EEC)
Modified by
- Commission Directive (EU) 2019/1833of 24 October 2019amending Annexes I, III, V and VI to Directive 2000/54/EC of the European Parliament and of the Council as regards purely technical adjustments, 32019L1833, October 31, 2019
- Commission Directive (EU) 2020/739of 3 June 2020amending Annex III to Directive 2000/54/EC of the European Parliament and of the Council as regards the inclusion of SARS-CoV-2 in the list of biological agents known to infect humans and amending Commission Directive (EU) 2019/1833, 32020L0739, June 4, 2020
(a) 'biological agents' shall mean micro-organisms, including those which have been genetically modified, cell cultures and human endoparasites, which may be able to provoke any infection, allergy or toxicity; (b) 'micro-organism' shall mean a microbiological entity, cellular or non-cellular, capable of replication or of transferring genetic material; (c) 'cell culture' shall mean the in-vitro growth of cells derived from multicellular organisms.
1. group 1 biological agent means one that is unlikely to cause human disease: 2. group 2 biological agent means one that can cause human disease and might be a hazard to workers; it is unlikely to spread to the community; there is usually effective prophylaxis or treatment available; 3. group 3 biological agent means one that can cause severe human disease and present a serious hazard to workers; it may present a risk of spreading to the community, but there is usually effective prophylaxis or treatment available; 4. group 4 biological agent means one that causes severe human disease and is a serious hazard to workers; it may present a high risk of spreading to the community; there is usually no effective prophylaxis or treatment available.
(a) classification of biological agents which are or may be a hazard to human health, as referred to in Article 18; (b) recommendations from a competent authority which indicate that the biological agent should be controlled in order to protect workers' health when workers are or may be exposed to such a biological agent as a result of their work; (c) information on diseases which may be contracted as a result of the work of the workers; (d) potential allergenic or toxigenic effects as a result of the work of the workers; (e) knowledge of a disease from which a worker is found to be suffering and which has a direct connection with his work.
(a) keeping as low as possible the number of workers exposed or likely to be exposed; (b) design of work processes and engineering control measures so as to avoid or minimise the release of biological agents into the place of work; (c) collective protection measures and/or, where exposure cannot be avoided by other means, individual protection measures; (d) hygiene measures compatible with the aim of the prevention or reduction of the accidental transfer or release of a biological agent from the workplace; (e) use of the biohazard sign depicted in Annex II and other relevant warning signs; (f) drawing up plans to deal with accidents involving biological agents; (g) testing, where it is necessary and technically possible, for the presence, outside the primary physical confinement, of biological agents used at work; (h) means for safe collection, storage and disposal of waste by workers including the use of secure and identifiable containers, after suitable treatment where appropriate; (i) arrangements for the safe handling and transport of biological agents within the workplace.
(a) the results of the assessment; (b) the activities in which workers have been exposed or may have been exposed to biological agents; (c) the number of workers exposed; (d) the name and capabilities of the person responsible for safety and health at work; (e) the protective and preventive measures taken, including working procedures and methods; (f) an emergency plan for the protection of workers from exposure to group 3 or a group 4 biological agent which might result from a loss of physical containment.
(a) workers do not eat or drink in working areas where there is a risk of contamination by biological agents; (b) workers are provided with appropriate protective clothing or other appropriate special clothing; (c) workers are provided with appropriate and adequate washing and toilet facilities, which may include eye washes and/or skin antiseptics; (d) any necessary protective equipment is: properly stored in a well-defined place, checked and cleaned if possible before, and in any case after, each use, is repaired, where defective, or is replaced before further use;
(e) procedures are specified for taking, handling and processing samples of human or animal origin.
(a) potential risks to health; (b) precautions to be taken to prevent exposure; (c) hygiene requirements; (d) wearing and use of protective equipment and clothing; (e) steps to be taken by workers in the case of incidents and to prevent incidents.
(a) given at the beginning of work involving contact with biological agents, (b) adapted to take account of new or changed risks, and (c) repeated periodically if necessary.
(a) a serious accident or incident involving the handling of a biological agent; (b) handling a group 4 biological agent.
(a) with biological agents known to be capable of establishing persistent or latent infections; (b) that, in the light of present knowledge, are undiagnosable until illness develops many years later; (c) that have particularly long incubation periods before illness develops; (d) that result in illnesses which recrudesce at times over a long period despite treatment, or (e) that may have serious long-term sequelae, the list shall be kept for an appropriately longer time up to 40 years following the last known exposure.
(a) group 2 biological agents; (b) group 3 biological agents; (c) group 4 biological agents.
(a) the name and address of the undertaking and/or establishment; (b) the name and capabilities of the person responsible for safety and health at work; (c) the results of the assessment referred to in Article 3; (d) the species of the biological agent; (e) the protection and preventive measures that are envisaged.
(a) prior to exposure; (b) at regular intervals thereafter.
(a) workers shall have access to the results of the health surveillance which concern them, and (b) the workers concerned or the employer may request a review of the results of the health surveillance.
(a) uncertainties about the presence of biological agents in human patients or animals and the materials and speciments taken from them; (b) the hazard represented by biological agents known or suspected to be present in human patients or animals and materials and specimens taken from them; (c) the risks posed by the nature of the work.
(a) specifying appropriate decontamination and disinfection procedures, and (b) implementing procedures enabling contaminated waste to be handled and disposed of without risk.
(a) Laboratories carrying out work which involves the handling of group 2, 3 or 4 biological agents for research, development, teaching or diagnostic purposes shall determine the containment measures in accordance with Annex V, in order to minimise the risk of infection. (b) Following the assessment referred to in Article 3, measures shall be determined in accordance with Annex V, after fixing the physical containment level required for the biological agents according to the degree of risk. Activities involving the handling of a biological agent must be carried out: only in working areas corresponding to at least containment level 2, for a group 2 biological agent, only in working areas corresponding to at least containment level 3, for a group 3 biological agent, only in working areas corresponding to at least containment level 4, for a group 4 biological agent.
(c) Laboratories handling materials in respect of which there exist uncertainties about the presence of biological agents which may cause human disease but which do not have as their aim working with biological agents as such (i.e. cultivating or concentrating them) should adopt containment level 2 at least. Containment levels 3 or 4 must be used, when appropriate, where it is known or it is suspected that they are necessary, except where guidelines provided by the competent national authorities show that, in certain cases, a lower containment level is appropriate.
(a) The containment principles set out in the second subparagraph of paragraph 1(b) should also apply to industrial processes on the basis of the practical measures and appropriate procedures given in Annex VI. (b) In accordance with the assessment of the risk linked to the use of group 2, 3 or 4 biological agents, the competent authorities may decide on appropriate measures which must be applied to the industrial use of such biological agents.
1. Work in food production plants. 2. Work in agriculture. 3. Work activities where there is contact with animals and/or products of animal origin. 4. Work in healthcare, including isolation and post-mortem units. 5. Work in clinical, veterinary and diagnostic laboratories, excluding diagnostic microbiological laboratories. 6. Work in refuse disposal plants. 7. Work in sewage purification installations.
A: Possible allergic effects D: List of workers exposed to this biological agent to be kept for more than 10 years after the end of last known exposure T: Toxin production V: Effective vaccine available and registered within the EU
Biological agent | Classification | Notes |
---|---|---|
W | ||
2 | ||
2 | ||
2 | ||
2 | ||
2 | ||
2 | ||
2 | ||
2 | ||
3 | T | |
2 | ||
2 | ||
2 | ||
2 | ||
2 | ||
2 | ||
2 | ||
2 | T, V | |
2 | ||
2 | ||
2 | ||
2 | ||
2 | ||
2 | ||
3 | ||
3 | ||
3 | ||
3 | ||
3 | ||
2 | ||
3 | ||
3 | D | |
2 | ||
2 | ||
2 | ||
2 | ||
2 | ||
2 | ||
2 | ||
2 | ||
2 | ||
2 | ||
2 | ||
3 | ||
2 | ||
2 | ||
2 | T | |
2 | T | |
2 | T | |
2 | T, V | |
2 | ||
2 | T, V | |
2 | ||
2 | T | |
2 | T | |
2 | ||
3 | ||
2 | ||
2 | ||
2 | ||
2 | ||
2 | ||
2 | ||
2 | ||
2 | ||
2 | ||
2 | ||
3 | T | |
2 | ||
2 | ||
2 | ||
2 | ||
2 | ||
3 | ||
2 | ||
2 | ||
2 | ||
2 | ||
2 | V | |
2 | ||
2 | ||
2 | ||
2 | ||
2 | ||
2 | ||
2 | ||
2 | ||
2 | ||
2 | ||
2 | ||
2 | ||
2 | ||
2 | ||
2 | ||
2 | ||
2 | ||
2 | ||
2 | ||
2 | ||
3 | V | |
2 | ||
2 | ||
2 | ||
3 | V | |
3 | ||
2 | ||
2 | ||
2 | ||
2 | ||
2 | ||
3 | ||
2 | ||
2 | ||
3 | ||
3 | ||
2 | ||
2 | ||
2 | ||
3 | V | |
3 | ||
2 | ||
2 | ||
2 | ||
2 | ||
2 | ||
2 | V | |
2 | ||
2 | ||
2 | ||
2 | ||
2 | ||
2 | ||
2 | ||
3 | ||
2 | ||
2 | ||
2 | ||
2 | ||
2 | ||
2 | ||
2 | ||
2 | ||
2 | ||
2 | ||
2 | ||
2 | ||
2 | ||
2 | ||
2 | T | |
2 | ||
3 | ||
3 | ||
3 | ||
2 | ||
3 | ||
3 | ||
3 | ||
2 | ||
3 | ||
3 | ||
3 | ||
3 | ||
2 | ||
2 | ||
2 | ||
2 | V | |
3 | V | |
2 | ||
2 | ||
2 | ||
3 | T | |
2 | ||
2 | ||
2 | ||
2 | T | |
2 | ||
2 | ||
2 | ||
2 | T, V | |
2 | T | |
2 | ||
2 | ||
2 | ||
2 | ||
2 | ||
2 | ||
2 | ||
2 | ||
2 | ||
2 | T, V | |
2 | ||
2 | ||
2 | ||
2 | ||
3 | ||
2 | ||
2 |
Classification | Notes | |
---|---|---|
Bunyavirales (O) | ||
Orthohantavirus (G) | ||
Andes orthohantavirus (Hantavirus species causing Hantavirus Pulmonary Syndrome [HPS]) | 3 | |
Bayou orthohantavirus | 3 | |
Black Creek Canal orthohantavirus | 3 | |
Cano Delgadito orthohantavirus | 3 | |
Choclo orthohantavirus | 3 | |
Dobrava-Belgrade orthohantavirus (Hantavirus species causing Haemorrhagic Fever with Renal Syndrome [HFRS]) | 3 | |
El Moro Canyon orthohantavirus | 3 | |
Hantaan orthohantavirus (Hantavirus species causing Haemorrhagic Fever with Renal Syndrome [HFRS]) | 3 | |
Laguna Negra orthohantavirus | 3 | |
Prospect Hill orthohantavirus | 2 | |
Puumala orthohantavirus (Hantavirus species causing Nephropathia Epidemica [NE]) | 2 | |
Seoul orthohantavirus (Hantavirus species causing Haemorrhagic Fever with Renal Syndrome [HFRS]) | 3 | |
Sin Nombre orthohantavirus (Hantavirus species causing Hantavirus Pulmonary Syndrome [HPS]) | 3 | |
Other hantaviruses known to be pathogenic | 2 | |
Orthonairovirus (G) | ||
Crimean-Congo haemorrhagic fever orthonairovirus | 4 | |
Dugbe orthonairovirus | 2 | |
Hazara orthonairovirus | 2 | |
Nairobi sheep disease orthonairovirus | 2 | |
Other nairoviruses known to be pathogenic | 2 | |
Orthobunyavirus (G) | ||
Bunyamwera orthobunyavirus (Germiston virus) | 2 | |
California encephalitis orthobunyavirus | 2 | |
Oropouche orthobunyavirus | 3 | |
Other orthobunyaviruses known to be pathogenic | 2 | |
Phlebovirus (G) | ||
Bhanja phlebovirus | 2 | |
Punta Toro phlebovirus | 2 | |
Rift Valley fever phlebovirus | 3 | |
Sandfly fever Naples phlebovirus (Toscana Virus) | 2 | |
SFTS phlebovirus (Severe Fever with Thrombocytopenia Syndrome-Virus) | 3 | |
Other phleboviruses known to be pathogenic | 2 | |
Herpesvirales (O) | ||
Cytomegalovirus (G) | ||
Human betaherpesvirus 5 (Cytomegalovirus) | 2 | |
Lymphocryptovirus (G) | ||
Human gammaherpesvirus 4 (Epstein-Barr virus) | 2 | |
Rhadinoovirus (G) | ||
Human gammaherpesvirus 8 | 2 | D |
Roseolovirus (G) | ||
Human betaherpesvirus 6A (Human B-lymphotropic virus) | 2 | |
Human betaherpesvirus 6B | 2 | |
Human betaherpesvirus 7 | 2 | |
Simplexvirus (G) | ||
Macacine alphaherpesvirus 1 (Herpesvirus simiae, Herpes B virus) | 3 | |
Human alphaherpesvirus 1 (Human herpesvirus 1, Herpes simplex virus type 1) | 2 | |
Human alphaherpesvirus 2 (Human herpesvirus 2, Herpes simplex virus type 2) | 2 | |
Varicellovirus (G) | ||
Human alphaherpesvirus 3 (Herpesvirus varicella-zoster) | 2 | V |
Mononegavirales (O) | ||
Ebolavirus (G) | 4 | |
Marburgvirus (G) | ||
Marburg marburgvirus | 4 | |
Avulavirus (G) | ||
Newcastle disease virus | 2 | |
Henipavirus (G) | ||
Hendra henipavirus | 4 | |
Nipah henipavirus | 4 | |
Morbillivirus (G) | ||
Measles morbillivirus | 2 | V |
Respirovirus (G) | ||
Human respirovirus 1 (Parainfluenza virus 1) | 2 | |
Human respirovirus 3 (Parainfluenza virus 3) | 2 | |
Rubulavirus (G) | ||
Mumps rubulavirus | 2 | V |
Human rubulavirus 2 (Parainfluenza virus 2) | 2 | |
Human rubulavirus 4 (Parainfluenza virus 4) | 2 | |
Metapneumovirus (G) | ||
Orthopneumovirus (G) | ||
Human orthopneumovirus (Respiratory syncytial virus) | 2 | |
Lyssavirus (G) | ||
Australian bat lyssavirus | 3 | V |
Duvenhage lyssavirus | 3 | V |
European bat lyssavirus 1 | 3 | V |
European bat lyssavirus 2 | 3 | V |
Lagos bat lyssavirus | 3 | |
Mokola lyssavirus | 3 | |
Rabies lyssavirus | 3 | V |
Vesiculovirus (G) | ||
Vesicular stomatitis virus, Alagoas vesiculovirus | 2 | |
Vesicular stomatitis virus, Indiana vesiculovirus | 2 | |
Vesicular stomatitis virus, New Jersey vesiculovirus | 2 | |
Piry vesiculovirus (Piry virus) | 2 | |
Nidovirales (O) | ||
Betacoronavirus (G) | ||
Severe acute respiratory syndrome-related coronavirus (SARS-virus) | 3 | |
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) | 3 | |
Middle East respiratory syndrome coronavirus (MERS-virus) | 3 | |
Other | 2 | |
Picornavirales (O) | ||
Cardiovirus (G) | ||
Saffold virus | 2 | |
Cosavirus (G) | ||
Cosavirus A | 2 | |
Enterovirus (G) | ||
Enterovirus A | 2 | |
Enterovirus B | 2 | |
Enterovirus C | 2 | |
Enterovirus D, Human Enterovirus type 70 (Acute haemorrhagic conjunctivitis virus) | 2 | |
Rhinoviruses | 2 | |
Poliovirus, type 1 and 3 | 2 | V |
Poliovirus, type 2 | 3 | V |
Hepatovirus (G) | ||
Hepatovirus A (Hepatitis A virus, Human Enterovirus type 72) | 2 | V |
Kobuvirus (G) | ||
Aichivirus A (Aichi virus 1) | 2 | |
Parechovirus (G) | ||
Parechoviruses A | 2 | |
Parechoviruses B (Ljungan virus) | 2 | |
Other | 2 | |
Unassigned (O) | ||
2 | ||
2 | ||
Mammarenavirus (G) | ||
Brazilian mammarenavirus | 4 | |
Chapare mammarenavirus | 4 | |
Flexal mammarenavirus | 3 | |
Guanarito mammarenavirus | 4 | |
Junín mammarenavirus | 4 | |
Lassa mammarenavirus | 4 | |
Lujo mammarenavirus | 4 | |
Lymphocytic choriomeningitis mammarenavirus, neurotropic strains | 2 | |
Lymphocytic choriomeningitis mammarenavirus (other strains) | 2 | |
Machupo mammarenavirus | 4 | |
Mobala mammarenavirus | 2 | |
Mopeia mammarenavirus | 2 | |
Tacaribe mammarenavirus | 2 | |
Whitewater Arroyo mammarenavirus | 3 | |
Norovirus (G) | ||
Norovirus (Norwalk virus) | 2 | |
Other | 2 | |
Orthohepadnavirus (G) | ||
Hepatitis B virus | 3 | V, D |
Orthohepevirus (G) | ||
Orthohepevirus A (Hepatitis E virus) | 2 | |
Flavivirus (G) | ||
Dengue virus | 3 | |
Japanese encephalitis virus | 3 | V |
Kyasanur Forest disease virus | 3 | V |
Louping ill virus | 3 | |
Murray Valley encephalitis virus (Australia encephalitis virus) | 3 | |
Omsk haemorrhagic fever virus | 3 | |
Powassan virus | 3 | |
Rocio virus | 3 | |
St. Louis encephalitis virus | 3 | |
Tick-borne encephalitis virus | ||
Absettarov virus | 3 | |
Hanzalova virus | 3 | |
Hypr virus | 3 | |
Kumlinge virus | 3 | |
Negishi virus | 3 | |
Russian spring-summer encephalitis | 3 | V |
Tick-borne encephalitis virus Central European subtype | 3 | V |
Tick-borne encephalitis virus Far Eastern Subtype | 3 | |
Tick-borne encephalitis virus Siberian subtype | 3 | V |
Wesselsbron virus | 3 | |
West Nile fever virus | 3 | |
Yellow fever virus | 3 | V |
Zika virus | 2 | |
Other flaviviruses known to be pathogenic | 2 | |
Hepacivirus (G) | ||
Hepacivirus C (Hepatitis C virus) | 3 | D |
Gammainfluenzavirus (G) | ||
Influenza C virus | 2 | V |
Influenzavirus A (G) | ||
Highly Pathogenic Avian Influenza Viruses HPAIV (H5), e.g. H5N1 | 3 | |
Highly Pathogenic Avian Influenza Viruses HPAIV (H7), e.g. H7N7, H7N9 | 3 | |
Influenza A virus | 2 | V |
Influenza A virus A/New York/1/18 (H1N1) (Spanish flu 1918) | 3 | |
Influenza A virus A/Singapore/1/57 (H2N2) | 3 | |
Low Pathogenic Avian Influenza Virus (LPAI) H7N9 | 3 | |
Influenzavirus B (G) | ||
Influenza B virus | 2 | V |
Thogoto virus (G) | ||
Dhori virus (Tick-borne | 2 | |
Thogoto virus (Tick-borne | 2 | |
2 | D | |
Erythroparvovirus (G) | ||
Primate erythroparvovirus 1 (Human parvovirus, B 19 virus) | 2 | |
Betapolyomavirus (G) | ||
Human polyomavirus 1 (BK virus) | 2 | D |
Human polyomavirus 2 (JC virus) | 2 | D |
Molluscipoxvirus (G) | ||
Molluscum contagiosum virus | 2 | |
Orthopoxvirus (G) | ||
Cowpox virus | 2 | |
Monkeypox virus | 3 | V |
Vaccinia virus (incl. Buffalopox virus | 2 | |
Variola (major and minor) virus | 4 | V |
Parapoxvirus (G) | ||
Orf virus | 2 | |
Pseudocowpox virus (Milkers’ node virus, parapoxvirus bovis) | 2 | |
Yatapoxvirus (G) | ||
Tanapox virus | 2 | |
Yaba monkey tumor virus | 2 | |
Seadornavirus (G) | ||
Banna virus | 2 | |
Coltivirus (G) | 2 | |
Rotavirus | 2 | |
Orbivirus (G) | 2 | |
Deltaretrovirus (G) | ||
Primate T-lymphotropic virus 1 (Human T-cell lymphotropic virus, type 1) | 3 | D |
Primate T-lymphotropic virus 2 (Human T-cell lymphotropic virus, type 2) | 3 | D |
Lentivirus (G) | ||
Human immunodeficiency virus 1 | 3 | D |
Human immunodeficiency virus 2 | 3 | D |
Simian Immunodeficiency Virus (SIV) | 2 | |
Alphavirus (G) | ||
Cabassouvirus | 3 | |
Eastern equine encephalomyelitis virus | 3 | V |
Bebaru virus | 2 | |
Chikungunya virus | 3 | |
Everglades virus | 3 | |
Mayaro virus | 3 | |
Mucambo virus | 3 | |
Ndumu virus | 3 | |
O’nyong-nyong virus | 2 | |
Ross River virus | 2 | |
Semliki Forest virus | 2 | |
Sindbis virus | 2 | |
Tonate virus | 3 | |
Venezuelan equine encephalomyelitis virus | 3 | V |
Western equine encephalomyelitis virus | 3 | V |
Other alphaviruses known to be pathogenic | 2 | |
Rubivirus (G) | ||
Rubella virus | 2 | V |
Deltavirus (G) | ||
Hepatitis delta virus | 2 | V, D |
Biological agent | Classification | Notes |
---|---|---|
Agent of Creutzfeldt-Jakob disease | 3 | D |
Variant Agent of Creutzfeldt-Jakob disease | 3 | D |
Agent of Bovine Spongiform Encephalopathy (BSE) and other related animal TSEs | 3 | D |
Agent of Gerstmann-Sträussler-Scheinker syndrome | 3 | D |
Agent of Kuru | 3 | D |
Agent of Scrapie | 2 |
Biological agent | Classification | Notes |
---|---|---|
2 | ||
2 | ||
2 | ||
2 | ||
2 | A | |
2 | A | |
2 | A | |
2 | ||
2 | ||
3 | ||
2 | ||
2 | ||
2 | ||
2 | ||
2 | ||
2 | ||
2 | ||
2 | ||
2 | ||
2 | ||
2 | ||
2 | ||
2 | ||
2 | ||
2 | ||
3 | ||
3 | ||
3 | ||
3 | ||
2 | ||
2 | ||
2 | ||
2 | ||
2 | ||
2 | ||
2 | ||
2 | ||
2 | ||
2 | ||
2 | ||
3 | ||
3 | ||
3 | ||
3 | ||
2 | ||
2 | ||
3 | ||
2 | ||
2 | ||
2 | ||
2 | ||
2 | ||
2 | ||
2 | ||
2 | ||
3 | ||
2 | ||
2 | ||
2 | ||
2 | ||
2 | ||
2 | ||
3 | ||
3 | ||
2 | ||
2 | ||
2 | ||
2 | ||
2 | ||
2 | ||
2 | ||
2 | ||
2 | ||
2 | ||
3 | ||
2 | ||
2 | ||
2 | ||
2 | ||
2 | ||
2 | ||
2 | ||
2 | ||
2 | ||
2 | ||
2 | ||
2 | ||
2 | ||
3 | ||
3 | ||
2 |
Biological agent | Classification | Notes |
---|---|---|
2 | A | |
2 | A | |
2 | ||
3 | ||
3 | ||
2 | A | |
2 | ||
2 | ||
2 | ||
2 | ||
3 | ||
3 | ||
2 | ||
3 | A | |
3 | A | |
2 | A | |
2 | A | |
2 | ||
2 | ||
2 | A | |
2 | ||
2 | ||
3 | ||
3 | ||
3 | ||
2 | ||
2 | ||
2 | A | |
2 | ||
2 | ||
3 | A | |
3 | ||
2 | ||
3 | ||
2 | ||
2 | ||
2 | ||
2 | A | |
2 | A | |
2 | A | |
2 |
keeping records of a worker's medical and occupational history, a personalised assessment of the worker's state of health. where appropriate, biological monitoring, as well as detection of early and reversible effects.
A. Containment measures | B. Containment levels | ||
---|---|---|---|
2 | 3 | 4 | |
Workplace | |||
1. The workplace is to be separated from any other activities in the same building | No | Recommended | Yes |
2. The workplace is to be sealable to permit fumigation | No | Recommended | Yes |
Facilities | |||
3. Infected material including any animal is to be handled in a safety cabinet or isolation or other suitable containment | Where appropriate | Yes, where infection is by airborne route | Yes |
Equipment | |||
4. Input air and extract air to the workplace are to be filtered using (HEPA | No | Yes, on extract air | Yes, on input and extract air |
5. The workplace is to be maintained at an air pressure negative to atmosphere | No | Recommended | Yes |
6. Surfaces impervious to water and easy to clean | Yes, for bench and floor | Yes, for bench, floor and other surfaces determined by risk assessment | Yes, for bench, walls, floor and ceiling |
7. Surfaces resistant to acids, alkalis, solvents, disinfectants | Recommended | Yes | Yes |
System of work | |||
8. Access is to be restricted to nominated workers only | Recommended | Yes | Yes, via airlock |
9. Efficient vector control, for example rodents and insects | Recommended | Yes | Yes |
10. Specified disinfection procedures | Yes | Yes | Yes |
11. Safe storage of a biological agent | Yes | Yes | Yes, secure storage |
12. Personnel should shower before leaving the contained area | No | Recommended | Recommended |
Waste | |||
13. Validated inactivation process for the safe disposal of animal carcases | Recommended | Yes, on or off site | Yes, on site |
Other measures | |||
14. A laboratory is to contain its own equipment | No | Recommended | Yes |
15. An observation window, or, alternative, is to be present, so that occupants can be seen | Recommended | Recommended | Yes |
A. Containment measures | B. Containment levels | ||
---|---|---|---|
2 | 3 | 4 | |
General | |||
1. Viable organisms should be handled in a system which physically separates the process from the environment | Yes | Yes | Yes |
2. Exhaust gases from the closed system should be treated so as to: | Minimise release | Prevent release | Prevent release |
3. Sample collection, addition of materials to a closed system and transfer of viable organisms to another closed system, should be performed so as to: | Minimise release | Prevent release | Prevent release |
4. Bulk culture fluids should not be removed from the closed system unless the viable organisms have been: | Inactivated by validated chemical or physical means | Inactivated by validated chemical or physical means | Inactivated by validated chemical or physical means |
5. Seals should be designed so as to: | Minimise release | Prevent release | Prevent release |
6. The controlled area should be designed to contain spillage of the entire contents of the closed system | No | Recommended | Yes |
7. The controlled area should be sealable to permit fumigation | No | Recommended | Yes |
Facilities | |||
8. Decontamination and washing facilities should be provided for personnel | Yes | Yes | Yes |
Equipment | |||
9. Input air and extract air to the controlled area should be HEPA | No | Recommended | Yes |
10. The controlled area should be maintained at an air pressure negative to atmosphere | No | Recommended | Yes |
11. The controlled area should be adequately ventilated to minimise air contamination | Recommended | Recommended | Yes |
System of work | |||
12. Closed systems | Recommended | Recommended | Yes, and purpose-built |
13. Biohazard signs should be posted | Recommended | Yes | Yes |
14. Access should be restricted to nominated personnel only | Recommended | Yes | Yes, via an airlock |
15. Personnel should shower before leaving the controlled area | No | Recommended | Yes |
16. Personnel should wear protective clothing | Yes, work clothing | Yes | Yes, complete change |
Waste | |||
17. Effluent from sinks and showers should be collected and inactivated before release | No | Recommended | Yes |
18. Effluent treatment before final discharge | Inactivated by validated chemical or physical means | Inactivated by validated chemical or physical means | Inactivated by validated chemical or physical means |
Directive | Deadline for transposition |
---|---|
90/679/EEC | |
93/88/EEC | |
95/30/EC | |
97/59/EC | |
97/65/EC |
Directive 90/679/EEC | This Directive |
---|---|
Article 1 | Article 1 |
Article 2, point (a) | Article 2, first paragraph, point (a) |
Article 2, point (b) | Article 2, first paragraph, point (b) |
Article 2, point (c) | Article 2, first paragraph, point (c) |
Article 2, point (d) | Article 2, second paragraph |
Article 3(1) | Article 3(1) |
Article 3(2)(a) | Article 3(2), first subparagraph |
Article 3(2)(b) | Article 3(2), second subparagraph |
Article 3(2)(c) | Article 3(2), third subparagraph |
Article 3(2)(d) | Article 3(2), fourth subparagraph |
Article 3(3), first indent | Article 3(3)(a) |
Article 3(3), second indent | Article 3(3)(b) |
Article 3(3), third indent | Article 3(3)(c) |
Article 3(3), fourth indent | Article 3(3)(d) |
Article 3(3), fifth indent | Article 3(3)(e) |
Article 4 | Article 4 |
Article 5 | Article 5 |
Article 6 | Article 6 |
Article 7(1), first indent | Article 7(1)(a) |
Article 7(1), second indent | Article 7(1)(b) |
Article 7(1), third indent | Article 7(1)(c) |
Article 7(1), fourth indent | Article 7(1)(d) |
Article 7(1), fifth indent | Article 7(1)(e) |
Article 7(1), sixth indent | Article 7(1)(f) |
Article 7(2) | Article 7(2) |
Article 7(3) | Article 7(3) |
Article 8(1)(a) to (e) | Article 8(1)(a) to (e) |
Article 8(2)(a) | Article 8(2), first subparagraph |
Article 8(2)(b) | Article 8(2), second subparagraph |
Article 8(3) | Article 8(3) |
Article 9(1)(a) to (e) | Article 9(1)(a) to (e) |
Article 9(2), first indent | Article 9(2)(a) |
Article 9(2), second indent | Article 9(2)(b) |
Article 9(2), third indent | Article 9(2)(c) |
Article 10(1), first indent | Article 10(1)(a) |
Article 10(1), second indent | Article 10(1)(b) |
Article 10(2) to (6) | Article 10(2) to (6) |
Article 11(1) | Article 11(1) |
Article 11(2), second subparagraph, first indent | Article 11(2), second subparagraph, (a) |
Article 11(2), second subparagraph, second indent | Article 11(2), second subparagraph, (b) |
Article 11(2), second subparagraph, third indent | Article 11(2), second subparagraph, (c) |
Article 11(2), second subparagraph, fourth indent | Article 11(2), second subparagraph, (d) |
Article 11(2), second subparagraph, fifth indent | Article 11(2), second subparagraph, (e) |
Article 11(3) | Article 11(3) |
Article 12 | Article 12 |
Article 13(1), first indent | Article 13(1)(a) |
Article 13(1), second indent | Article 13(1)(b) |
Article 13(1), third indent | Article 13(1)(c) |
Article 13(2) to (4) | Article 13(2) to (4) |
Article 14(1) | Article 14(1) |
Article 14(2), first indent | Article 14(2)(a) |
Article 14(2), second indent | Article 14(2)(b) |
Article 14(3) to (6) | Article 14(3) to (6) |
Article 14(7), first indent | Article 14(7)(a) |
Article 14(7), second indent | Article 14(7)(b) |
Article 14(8) | Article 14(8) |
Article 14(9) | Article 14(9) |
Article 15 | Article 15 |
Article 16(1) | Article 16(1) |
Article 16(2)(a) | Article 16(2)(a) |
Article 16(2)(b) | Article 16(2)(b) |
Article 16(2)(c) | Article 16(3) |
Article 17 | Article 17 |
Article 18(1) | — |
Article 18(2) | Article 18(1) |
Article 18(3) | Article 18(2) |
Article 18(4) | Article 18(3) |
Article 19 | Article 19 |
Article 20(1) | — |
Article 20(2) | Article 20 |
— | Article 21 |
— | Article 22 |
— | Article 23 |
Annex I | Annex I |
Annex II | Annex II |
Annex III | Annex III |
Annex IV | Annex IV |
Annex V | Annex V |
Annex VI | Annex VI |
Annex VII | Annex VII |
— | Annex VIII |
— | Annex IX |